Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
4D Molecular Therapeutics, Inc. | CHIEF FINANCIAL & BUSINESS OFFICER | Stock Option (Right to Buy) | 75K | Dec 11, 2023 | Direct | ||
Myovant Sciences Ltd. | Principal Financial Officer | Common Shares | 0 | $27.00 | Mar 10, 2023 | Direct | |
Myovant Sciences Ltd. | Principal Financial Officer | Performance Stock Unit | 0 | Mar 10, 2023 | Direct | ||
Myovant Sciences Ltd. | Principal Financial Officer | Stock Options (Right to Buy) | 0 | Mar 10, 2023 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
FDMT | 4D Molecular Therapeutics, Inc. | Dec 11, 2023 | 1 | $0 | 4 | Dec 13, 2023 | CHIEF FINANCIAL & BUSINESS OFFICER |
FDMT | 4D Molecular Therapeutics, Inc. | Oct 1, 2023 | 1 | $0 | 4 | Oct 3, 2023 | CHIEF FINANCIAL & BUSINESS OFFICER |
FDMT | 4D Molecular Therapeutics, Inc. | Sep 22, 2023 | 0 | $0 | 3 | Sep 26, 2023 | CHIEF FINANCIAL & BUSINESS OFFICER |
MYOV | Myovant Sciences Ltd. | Mar 10, 2023 | 4 | $0 | 4 | Mar 10, 2023 | Principal Financial Officer |
MYOV | Myovant Sciences Ltd. | Dec 16, 2022 | 1 | -$59.9K | 4 | Dec 20, 2022 | Principal Financial Officer |
MYOV | Myovant Sciences Ltd. | Sep 16, 2022 | 1 | -$174K | 4 | Sep 20, 2022 | Principal Financial Officer |
MYOV | Myovant Sciences Ltd. | Apr 15, 2022 | 1 | $0 | 4 | Apr 19, 2022 | Principal Financial Officer |
MYOV | Myovant Sciences Ltd. | Sep 15, 2021 | 2 | $0 | 4 | Sep 17, 2021 | Principal Financial Officer |
MYOV | Myovant Sciences Ltd. | Sep 7, 2021 | 0 | $0 | 3 | Sep 9, 2021 | Principal Financial Officer |